{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-135766","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.371629+00:00","generated_at":"2026-05-15T07:58:10.415666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TuHURA FY2025 cash $3.6M, R&D $20.5M; Phase 3 MCC trial ongoing; Kineta acquired","bullets":["Cash $3.6M at Dec 31, 2025; additional $7.5M from 2025 registered direct offering received Q1 2026.","R&D expenses $20.5M for FY2025 vs $14.7M in FY2024; operating cash outflow $27.7M.","Phase 3 trial of IFx-2.0 in Merkel cell carcinoma initiated under FDA SPA; enrollment estimated to complete mid-2027.","Closed $10.5M acquisition of Kineta, gaining VISTA antibody TBS-2025; $21.2M raised in 2025 offerings.","Upcoming milestones: FDA meeting for TBS-2025 in June 2026; ADC lead selection in 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-135766","json":"https://secwatch.observer/filing/0001193125-26-135766.json","markdown":"https://secwatch.observer/filing/0001193125-26-135766.md","text":"https://secwatch.observer/filing/0001193125-26-135766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/0001193125-26-135766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/hura-20260401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:58:10.415666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1756e40f9060353179e9eb464bf5848ebe28572c","claim":"TuHURA Biosciences, Inc./NV reported financial results for for the Company's fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/0001193125-26-135766-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the Company's fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}]},{"claim_id":"a4970c411b1d1890c548375713a0b188b1b7eb00","claim":"TuHURA Biosciences, Inc./NV reported financial results for for the year ended December 31, 2025.","evidence_excerpt":"On April 1, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the year ended December 31, 2025, and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/0001193125-26-135766-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2025"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}